Poster Schedule

7:00 AM – 1:45 PM MST

(W-001) Leveraging quantitative systems pharmacology (QSP) modeling to understand effects of corticosteroids on immune cells and cytokine release following administration of SC Epcoritamab

Favorite

7:00 AM – 1:45 PM MST

(W-002) Dual Physiologically-based Pharmacokinetics Models of Nano-Liposomal (Nal-IRI) and Non-Liposomal Irinotecan in Ewing’s Family Tumor Xenograft

Favorite

7:00 AM – 1:45 PM MST

(W-003) Leveraging Machine Learning and Real-World Data: Time-to-Event Analysis of COVID-19 Patients Using Electronic Health Records

Favorite

7:00 AM – 1:45 PM MST

(W-004) Development of QSP model of non-small cell lung cancer and its application to support optimal dose selection for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1

Favorite

7:00 AM – 1:45 PM MST

(W-005) Utilizing PBPK/RO model for description of GEN1042 (BNT312) PK and prediction of trimer level to guide dose selection

Favorite

7:00 AM – 1:45 PM MST

(W-006) Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab

Favorite

7:00 AM – 1:45 PM MST

(W-007) Simulating Adaptive Dosing Regimens from PK and PKPD Models Using mrgsolve

Favorite

7:00 AM – 1:45 PM MST

(W-008) The reference corrected VPC (rcVPC) - An informative model diagnostic for assessing underlying exposure-response relationships

Favorite

7:00 AM – 1:45 PM MST

(W-009) A Physiological-Based Pharmacokinetic (PBPK) Model embedded with Pulmonary Compartmental Absorption and Transit (PCAT™️) Module to Predict Intranasal Ketamine Pharmacokinetics in Pediatric Population

Favorite

7:00 AM – 1:45 PM MST

(W-010) Modeling the evolution of activation marker distributions in flow cytometry data representing cell populations in patients dosed with immunomodulating agents

Favorite

7:00 AM – 1:45 PM MST

(W-011) Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections

Favorite

7:00 AM – 1:45 PM MST

(W-012) Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions

Favorite

7:00 AM – 1:45 PM MST

(W-013) Patent Ductus Arteriosus in Preterm Infants: Exploring Optimal Acetaminophen Dosing for Oral and Rectal Administration

Favorite

7:00 AM – 1:45 PM MST

(W-014) Model-Based Meta Analysis for the IPSOS Trial in Platinum Ineligible NSCLC Patients

Favorite

7:00 AM – 1:45 PM MST

(W-015) Eculizumab as a Key Comparator for the Evaluation of Complement Targeted Novel Therapeutic Strategies with a QSP Model

Favorite

7:00 AM – 1:45 PM MST

(W-016) Revumenib physiologically based pharmacokinetic model for evaluation of age effect and CYP3A4-mediated drug-drug interaction in relapsed/refractory acute leukemias

Favorite

7:00 AM – 1:45 PM MST

(W-017) Integrating mathematical modeling with multiplexed immunofluorescence data to predict drug-induced cell arrest

Favorite

7:00 AM – 1:45 PM MST

(W-018) Novel computational workflow for selecting virtual patient cohorts for in silico clinical trials

Favorite

7:00 AM – 1:45 PM MST

(W-019) Phase 1 Interim Population Pharmacokinetic/Pharmacodynamic Model and Phase 2 Dose Exploration for IMM-1-104, a Novel Concept Oral Deep Cyclic MEK Inhibitor.

Favorite

7:00 AM – 1:45 PM MST

(W-020) In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models

Favorite

7:00 AM – 1:45 PM MST

(W-021) Local TMDD of large molecules in tissue interstitial space

Favorite

7:00 AM – 1:45 PM MST

(W-022) Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease

Favorite

7:00 AM – 1:45 PM MST

(W-023) Optimized Noncompartmental Half-Life Estimation with Tobit Regression

Favorite

7:00 AM – 1:45 PM MST

(W-024) Small molecule exposure prediction (intravenous (IV) and oral (PO)) using Machine learning (ML) in combination with mechanistic modeling.

Favorite

7:00 AM – 1:45 PM MST

(W-025) Population pharmacokinetic analysis of anti-interleukin-15 monoclonal antibody TEV-53408 in healthy volunteers

Favorite

7:00 AM – 1:45 PM MST

(W-026) Population pharmacokinetic and pharmacodynamic analysis of natural killer cell levels in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers

Favorite

7:00 AM – 1:45 PM MST

(W-027) Population Pharmacokinetic (PopPK) Model to Characterize Pharmacokinetics (PK) of Vepdegestrant, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Healthy Adult Participants

Favorite

7:00 AM – 1:45 PM MST

(W-028) Development and application of physiologically based pharmacokinetic model of darunavir on pregnant population

Favorite

7:00 AM – 1:45 PM MST

(W-029) Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case study

Favorite

7:00 AM – 1:45 PM MST

(W-030) Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02390 in Patients with Select Advanced Malignancies

Favorite

7:00 AM – 1:45 PM MST

(W-031) Scientific Project Management (SPM) to Enhance Model-Informed Drug Development

Favorite

7:00 AM – 1:45 PM MST

(W-032) Longitudinal Joint Modeling of Modified Mayo Score and Dropout in Patients with Moderate to Severely Active Ulcerative Colitis.

Favorite

7:00 AM – 1:45 PM MST

(W-033) Adaptation of a Published Kidney Disease QSP Model to Represent Autosomal-Dominant Polycystic Kidney Disease and Evaluate Treatment Options

Favorite

7:00 AM – 1:45 PM MST

(W-034) Parallel Tempering for Generation of Virtual Patients and Virtual Populations

Favorite

7:00 AM – 1:45 PM MST

(W-035) Systems model to predict fractional exhaled nitric oxide response to inhaled JAK inhibitors in patients with mild to moderate asthma

Favorite

7:00 AM – 1:45 PM MST

(W-036) Population Plasma and Urine Pharmacokinetic Data and Modelling of Casdatifan Supports Administration to Participants with Moderate Renal Impairment

Favorite

7:00 AM – 1:45 PM MST

(W-037) Evaluation of Large Language Models for an AI Chat Assistant Focused on Pumas and Pharmacometrics

Favorite

7:00 AM – 1:45 PM MST

(W-038) Development of a Physiologically-Based Pharmacokinetic (PBPK) Model for Caffeine in Pregnancy: Evaluating Neonatal Transfer

Favorite

7:00 AM – 1:45 PM MST

(W-039) Predictive Pharmacokinetic Analysis of Novel PLCG2 Inhibitors Using GastroPlus and ADMET Predictor

Favorite

7:00 AM – 1:45 PM MST

(W-040) Extracting Lab Value Reference Ranges from Neonatal Real-World Data in OMOP Format

Favorite

7:00 AM – 1:45 PM MST

(W-041) Inferring HIV rebound timing from a noisy biomarker

Favorite

7:00 AM – 1:45 PM MST

(W-042) Population Pharmacokinetic Modeling of Hydroxyurea in Plasma and Breast Milk in Lactating Women

Favorite

7:00 AM – 1:45 PM MST

(W-043) Early sBCMA Kinetics as a Potential Indicator of Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Patients Receiving CAR T-Cell Therapy

Favorite

7:00 AM – 1:45 PM MST

(W-044) Population Cellular Kinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Multiple Myeloma

Favorite

7:00 AM – 1:45 PM MST

(W-045) Clinical Trial Simulation to Assess Sample Size and Power For Detecting Differences in Pharmacokinetic Exposure Metrics

Favorite

7:00 AM – 1:45 PM MST

(W-046) Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Valemetostat Dose Recommendations in Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)

Favorite

7:00 AM – 1:45 PM MST

(W-047) Mechanistic PK/PD modeling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen (HBsAg) and ALT in participants with chronic hepatitis B infection to support Phase 3 study design

Favorite

7:00 AM – 1:45 PM MST

(W-048) Itacitinib Population Pharmacokinetics (PopPK) and Exposure-Response for Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy: Results From Phase 2 Study NCT04071366

Favorite

7:00 AM – 1:45 PM MST

(W-049) Exposure-Response Analysis for Hepatotoxicity of Rivoceranib Monotherapy and in Combination with Camrelizumab in Patients with Various Cancers, Including Advanced Hepatocellular Carcinoma

Favorite

7:00 AM – 1:45 PM MST

(W-050) Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analysis of Danicamtiv in Heart Failure with Reduced Ejection Fraction

Favorite

7:00 AM – 1:45 PM MST

(W-051) Model-based ‘learn and confirm approach’ demonstrates similarity of cemiplimab exposure in pediatric and adult populations

Favorite

7:00 AM – 1:45 PM MST

(W-052) Hybrid Minimal Physiological-Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites Disposition in Humans

Favorite

7:00 AM – 1:45 PM MST

(W-053) Development of physiologically based pharmacokinetic models for RET inhibitors to predict brain distribution

Favorite

7:00 AM – 1:45 PM MST

(W-054) Effects of sparse sampling in the characterization of leuprolide pharmacokinetics and pharmacodynamics in patients with prostate cancer

Favorite

7:00 AM – 1:45 PM MST

(W-055) Confounding Impact of Event-Driven Exposure Phenomenon on Summary Exposure Metrics in Time-to-Event Exposure Response Analyses

Favorite

7:00 AM – 1:45 PM MST

(W-056) Population Pharmacokinetics of Quemliclustat, a Potent, Selective, and Reversible CD73 Inhibitor, in Patients with Cancer

Favorite

7:00 AM – 1:45 PM MST

(W-057) Optimizing Drug Development: Assessing Small Language Models for Efficient Drug-Drug Interaction Data Extraction

Favorite

7:00 AM – 1:45 PM MST

(W-058) QSP-based virtual twin approach provides mechanistic insight into enzyme replacement therapies in Pompe Disease

Favorite

7:00 AM – 1:45 PM MST

(W-059) Facilitating RP2D decisions for CAR T cell therapy clinical studies using a QSP model

Favorite

7:00 AM – 1:45 PM MST

(W-060) Quantitative systems pharmacology model for distinguishing efficacy of anti-CD20 therapy variants in populations of Multiple Sclerosis patients

Favorite

7:00 AM – 1:45 PM MST

(W-061) Quantitative systems pharmacology modeling of neurotoxicity and cognitive scores in Alzheimer’s disease for prediction of therapy outcomes

Favorite

7:00 AM – 1:45 PM MST

(W-062) SEMI-PHYSIOLOGIC POPULATION PHARMACOKINETIC MODEL TO EVALUATE THE EFFECT OF HEPATIC-UPTAKE TRANSPORTER GENE SLC22A1 POLYMORPHISM ON PHARMACOKINETICS OF PROGUANIL AND ITS METABOLITE, CYCLOGUANIL

Favorite

7:00 AM – 1:45 PM MST

(W-063) Cell-line Specific Network Modeling to Assess Differential Signal Transduction of Oxaliplatin-based Drug Combinations for Colorectal Cancer

Favorite

7:00 AM – 1:45 PM MST

(W-064) Comparative evaluation of different vancomycin population pharmacokinetic models to predict Bayesian-estimated vancomycin AUC in Korean patients

Favorite

7:00 AM – 1:45 PM MST

(W-065) Extrapolation of Efficacy and Simplification and Optimization of Pediatric Clinical Trial Design for Azilsartan Medoxomil (Edarbi) through Modeling and Simulation

Favorite

7:00 AM – 1:45 PM MST

(W-066) PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF PIOGLITAZONE: EVALUATING THE EFFECT OF THE CYTOCHROME P450 2C8*2 SINGLE NUCLEOTIDE POLYMORPHISM

Favorite

7:00 AM – 1:45 PM MST

(W-067) Gauss-Hermite cohort population estimation of dexamethasone pharmacokinetic parameters in pregnant women using blood samples collected at birth

Favorite

7:00 AM – 1:45 PM MST

(W-068) Dose determination of Lutathera in adolescents via popPK and dosimetry modeling and simulation

Favorite

7:00 AM – 1:45 PM MST

(W-069) Exploring Appropriate Prior Distributions for Covariance Matrix Estimation in Bayesian Population Pharmacokinetic Analysis

Favorite

7:00 AM – 1:45 PM MST

(W-070) Concentration-QTc Analysis of PF-07220060 in Patients with Advanced Solid Tumors

Favorite

7:00 AM – 1:45 PM MST

(W-071) Mathematical modeling can help to successfully translate preclinical findings in mice models of asthma into first-in-human trials

Favorite

7:00 AM – 1:45 PM MST

(W-072) Unraveling Major Inflammatory Cytokines Serum Distribution Patterns in Systemic Lupus Erythematosus Patients: Insights from the CYTOCON Database

Favorite

7:00 AM – 1:45 PM MST

(W-073) xplorer: a Flexible Shiny App for Data Visualization, Exploration and Quality Assurance

Favorite

7:00 AM – 1:45 PM MST

(W-074) Exposure-response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Favorite

7:00 AM – 1:45 PM MST

(W-075) Population pharmacokinetic modeling to support dose selection of rimegepant in pediatrics

Favorite

7:00 AM – 1:45 PM MST

(W-076) Interactive Pharmacometric Simulations and Model Exploration with e-Campsis

Favorite

7:00 AM – 1:45 PM MST

(W-077) An Introduction to Campsis: The R-Based Open-Source PK/PD Simulation Suite

Favorite

7:00 AM – 1:45 PM MST

(W-078) Effect of Convenience Sampling on Overall Drug Exposure during Pregnancy

Favorite

7:00 AM – 1:45 PM MST

(W-079) Characterizing Pharmacokinetics Effects on Measures of Overall Drug Exposure during Pregnancy

Favorite

7:00 AM – 1:45 PM MST

(W-080) Comparison of common methodologies for accounting for IIV for oral bioavailability (F) in the absence of intravenous data

Favorite

7:00 AM – 1:45 PM MST

(W-081) Quantifying dengue natural immunity and probability of disease using serum antibody titers

Favorite

7:00 AM – 1:45 PM MST

(W-082) Population Pharmacokinetic and Exposure-Response Analyses of Alectinib and Its Metabolite M4 to Support Dose Selection in Patients with Resected Stage IB - IIIA ALK-Positive Non-Small Cell Lung Cancer

Favorite

7:00 AM – 1:45 PM MST

(W-083) Model-based Meta-Analysis (MBMA) to Inform Immuotherapy (IO) Treatment Decisions in Metastatic Non-Small Cell Lung Cancer (mNSCLC)

Favorite

7:00 AM – 1:45 PM MST

(W-084) Exploring the feasibility of using AI to identify patient characteristics predictive of histological endpoints in metabolic dysfunction associated steatohepatitis (MASH)

Favorite

7:00 AM – 1:45 PM MST

(W-085) The Influence of Systematic and Technical Errors on Population Pharmacokinetic / Pharmacodynamic Model Parameters: Nonlinear Mixed-Effect Approach

Favorite

7:00 AM – 1:45 PM MST

(W-086) Prediction of progression free survival using tumor growth inhibition models: Effect of model uncertainty, inter-individual variability and observational noise on prediction accuracy

Favorite

7:00 AM – 1:45 PM MST

(W-087) Comparison of empirical and physiologically-based modeling approaches to explore mechanisms of drug-drug interaction between abemaciclib and olaparib in a small cohort of patients with ovarian cancer

Favorite

7:00 AM – 1:45 PM MST

(W-088) pmparams: an R Package for Defining and Formatting Parameter Tables in Pharmacometric Modeling

Favorite

7:00 AM – 1:45 PM MST

(W-089) Modeling Lenacapavir (LEN) Exposure After Daily Oral Administration Alone and in Combination with Bictegravir (BIC) in People with HIV: A Population Pharmacokinetic Approach

Favorite

7:00 AM – 1:45 PM MST

(W-090) Physiologically Based Pharmacokinetic Model of Vedolizumab in Adult Patients with Inflammatory Bowel Disease

Favorite

7:00 AM – 1:45 PM MST

(W-091) Characterization of the Effect of Biofilm Formation on the Antimicrobial Activity of Tigecycline against M. abscessus using a Hollow Fiber Infection Model and Pharmacokinetic/Pharmacodynamic Modeling

Favorite

7:00 AM – 1:45 PM MST

(W-092) Incorporating Computational Fluid Dynamic Modeling into Pharmacometrics Models for Applications to Gene Therapy, Anti-Inflammatory Treatments and Transdermal Patch Drug Delivery

Favorite

7:00 AM – 1:45 PM MST

(W-093) Integration of Population Pharmacokinetic Model for Tenofovir Alafenamide by External Evaluation

Favorite

7:00 AM – 1:45 PM MST

(W-094) Population Pharmacokinetic/Pharmacodynamic Analysis of Cemdisiran (ALN-CC5) in Healthy Subjects and Patients with Immunoglobulin A Nephropathy

Favorite

7:00 AM – 1:45 PM MST

(W-095) Physiologically Based Pharmacokinetic (PBPK) modeling of hepatic impairment using PK-Sim

Favorite

7:00 AM – 1:45 PM MST

(W-096) Quantitative Systems Pharmacology of T-cell Engagers and Cytokine Release

Favorite

7:00 AM – 1:45 PM MST

(W-097) Predicting pharmacokinetic profile of small molecule drugs based on chemical structure using machine learning.

Favorite

7:00 AM – 1:45 PM MST

(W-098) Role of quantitative systems pharmacology (QSP) in optimizing elranatamab dosing regimen for relapsed/refractory multiple myeloma

Favorite

7:00 AM – 1:45 PM MST

(W-099) Constructing a virtual control arm and evaluating operating characteristics using TGI metrics to support go/no-go decisions for single-arm Phase Ib/II combination studies

Favorite

7:00 AM – 1:45 PM MST

(W-100) Pharmacometrics-Based Evaluation of Fixed versus Weight-Based Dosing Strategies for Approved Antibody Drug Conjugates (ADC)

Favorite

7:00 AM – 1:45 PM MST

(W-101) Development of a Population PK model for an inhaled drug

Favorite

7:00 AM – 1:45 PM MST

(W-102) Mathematical optimization of a thrombopoiesis quantitative systems pharmacology (QSP) model

Favorite

7:00 AM – 1:45 PM MST

(W-103) Prediction of the Biological Effect of PEG-rHuEPO Candidates in Chronic Kidney Disease Patients using a Middle-out Translation Approach

Favorite

7:00 AM – 1:45 PM MST

(W-104) Modeling Endothelial Cell-Targeted Polymeric Nanoparticle Delivery in Renal Glomeruli

Favorite

7:00 AM – 1:45 PM MST

(W-105) Informing Early Trial Design in Oncology Through Clinical Trial Simulations from Population Pharmacokinetic-Tumor Growth Inhibition Models

Favorite

7:00 AM – 1:45 PM MST

(W-106) Comparing Predicted Serotype-specific Vaccine Effectiveness of Pneumococcal Conjugate Vaccines V114 and PCV20 in Children using a novel model-based meta-analysis approach

Favorite

7:00 AM – 1:45 PM MST

(W-107) Mechanistic Modeling Of Surface Molecule Interactions: Impact Of Methodology On CAR-T Cell Dose Predictions

Favorite

7:00 AM – 1:45 PM MST

(W-108) Incorporating High Dimensional Gut Microbiome Data into Population Pharmacokinetic Modeling of Mycophenolate Mofetil

Favorite

7:00 AM – 1:45 PM MST

(W-109) Comparative Analysis of Minimal Physiologically Based Pharmacokinetic (mPBPK) and Traditional Pharmacokinetic (PK) Models in the Context of Quantitative Systems Pharmacology (QSP) for T-cell Engagers

Favorite

7:00 AM – 1:45 PM MST

(W-110) PK/PD Modeling of the Anti-FcRn Monoclonal Antibody Nipocalimab Administered to Healthy Subjects and Participants with Moderate to Severe Active Rheumatoid Arthritis

Favorite

7:00 AM – 1:45 PM MST

(W-111) Pharmacokinetics of Long-Acting Naltrexone in Pregnancy: Insights from Physiologically Based Pharmacokinetic Modeling

Favorite

7:00 AM – 1:45 PM MST

(W-112) Use of Model-Informed Drug Development (MIDD) to Support Dose Selection of Nivolumab in Combination with Ipilimumab in Adolescent Patients with MSI-H/dMMR Metastatic Colorectal Cancer

Favorite

7:00 AM – 1:45 PM MST

(W-113) Population Pharmacokinetic and Exposure-Response Analyses of Nivolumab in Combination with Ipilimumab to Support Dosing Regimen in Subjects with First-Line MSI-H/dMMR Metastatic Colorectal Cancer

Favorite

7:00 AM – 1:45 PM MST

(W-114) Consideration of Study design aspects in the creation of virtual populations for organ impairment studies: One size may not fit all

Favorite

7:00 AM – 1:45 PM MST

(W-115) Leveraging PBPK modeling to advance spironolactone complex disposition knowledge

Favorite

7:00 AM – 1:45 PM MST

(W-116) Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

Favorite

7:00 AM – 1:45 PM MST

(W-117) PMXModelStructuR: A Tool for Pharmacometrics Model Visualization in R

Favorite

7:00 AM – 1:45 PM MST

(W-118) Evaluation of the population pharmacokinetics of pexmetinib in a simultaneous model of two formulations

Favorite

7:00 AM – 1:45 PM MST

(W-119) Population pharmacokinetics of revumenib in patients with relapsed/refractory acute leukemias

Favorite

7:00 AM – 1:45 PM MST

(W-120) Quantitative Systems Pharmacology Modeling of X-linked Hypophosphatemia Disease Pathway Normalization to Predict the Impact of Burosumab Treatment on Serum Biomarkers in Adult and Pediatric Patients

Favorite

7:00 AM – 1:45 PM MST

(W-121) Model-informed simulations to determine optimal Piperacillin-Tazobactam Dosing regimens in Pediatric Perioperative Care: Effect of body size and renal function

Favorite

7:00 AM – 1:45 PM MST

(W-122) Dual Target-Mediated Drug Disposition Model to Guide the Selection of Starting Dose and Escalation in FTIH Trials for Volrustomig (MEDI5752), a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4

Favorite

7:00 AM – 1:45 PM MST

(W-123) Population pharmacokinetic analysis of Dato-DXd, a TROP2-targeting ADC, in NSCLC and HR-positive, HER2-negative breast cancer patients

Favorite

7:00 AM – 1:45 PM MST

(W-124) Real world examples of PBPK impact on CYP3A4 victim DDI drug label content

Favorite

7:00 AM – 1:45 PM MST

(W-125) Flux-based IVIVC for predicting oxybutynin exposure with and without occlusion of a transdermal gel

Favorite

7:00 AM – 1:45 PM MST

(W-126) Population Pharmacokinetics of Atomoxetine at Steady-State Dosing for ADHD Treatment in Children and Adolescents

Favorite

7:00 AM – 1:45 PM MST

(W-127) Population pharmacokinetic and pharmacodynamic modeling of free serum interleukin-15 in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers.

Favorite

7:00 AM – 1:45 PM MST

(W-128) Population pharmacokinetics and exposure-safety of DS-6157a in patients with advanced gastrointestinal stromal tumor (GIST)

Favorite

7:00 AM – 1:45 PM MST

(W-129) Frailty phenotype as a sensitive indicator of aging-related Cytochrome P450 3A functional changes：Application of dose optimization recommendations for ticagrelor in the Chinese frail older population

Favorite

7:00 AM – 1:45 PM MST

(W-130) Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus® to Predict Hepatic Concentrations

Favorite

7:00 AM – 1:45 PM MST

(W-131) Mechanistic modeling to inform T cell engager development for low copy targets

Favorite

7:00 AM – 1:45 PM MST

(W-132) Population Pharmacokinetic Modeling of IMP7068 in Patients with Advanced Solid Tumors

Favorite

7:00 AM – 1:45 PM MST

(W-133) Losing the Forest: Causal Shapley Additive Explanations for Interpretation of Population-Pharmacokinetic models

Favorite

7:00 AM – 1:45 PM MST

(W-134) Causal directed acyclic graph (DAG) application in exposure-response analyses

Favorite

7:00 AM – 1:45 PM MST

(W-135) PharmaInsight Explorer: Empowering EDA in Clinical Pharmacology and Safety Science

Favorite

7:00 AM – 1:45 PM MST

(W-136) Gompertz Cure Rate Survival Models with Stan and Brms

Favorite

7:00 AM – 1:45 PM MST

(W-137) Immune thrombocytopenia purpura (ITP) indication extension allowing for administration of Eltrombopag in adult patients who are refractory to 1L-treatment irrespective of time since diagnosis

Favorite

7:00 AM – 1:45 PM MST

(W-138) A model-based framework for assessing schedule dependence of therapeutic window for three-drug combinations

Favorite

7:00 AM – 1:45 PM MST

(W-139) Design and evaluation of a novel decision metric for estimating Phase 1 Maximum Tolerated Dose

Favorite

7:00 AM – 1:45 PM MST

(W-140) Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of VRC01 and VRC01LS in People Without HIV in a Phase 1 Clinical Trial (HVTN 116)

Favorite

7:00 AM – 1:45 PM MST

(W-141) Disease progression modeling of myositis from real-world data

Favorite

7:00 AM – 1:45 PM MST

(W-142) Population Pharmacokinetics and Exposure-response Analyses of Lazertinib in Combination with Amivantamab as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic NSCLC

Favorite